Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody

BACKGROUND: Aberrant MET tyrosine kinase signaling is known to cause cancer initiation and progression. While MET inhibitors are in clinical trials against several cancer types, the clinical efficacies are controversial and the molecular mechanisms toward sensitivity remain elusive. METHODS: With th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Transl Med
Autori principali: Kou, Jianqun, Musich, Phillip R., Staal, Ben, Kang, Liang, Qin, Yuan, Yao, Zhi Q., Zhang, Boheng, Wu, Weizhong, Tam, Angela, Huang, Alan, Hao, Huai-Xiang, Vande Woude, George F., Xie, Qian
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2018
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6134500/
https://ncbi.nlm.nih.gov/pubmed/30208970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-018-1628-y
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi